<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039699</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-ER-008</org_study_id>
    <nct_id>NCT03039699</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children</brief_title>
  <official_title>International Multicenter, Double-blind, Randomized, Parallel Group Placebo-Controlled Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to obtain additional data on efficacy and safety of Ergoferon in&#xD;
      the treatment of viral intestinal infections in inpatient children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: a multicenter, double-blind, placebo-controlled, randomized clinical trial in&#xD;
      parallel groups.&#xD;
&#xD;
      This study will enroll subjects of both sexes aged from 6 months to 6 years who are admitted&#xD;
      to hospital within 48 h of the onset of acute intestinal infection (AII), presumably of viral&#xD;
      aetiology. Patients to be enrolled in the screening will be children with typical viral&#xD;
      gastroenteritis/enteritis symptoms. The key symptom is decreased in the consistency of stools&#xD;
      (loose or liquid) and increased in the frequency of its evacuations (at list 3 time daily).&#xD;
      Virus detection in stool samples will be performed by polymerase chain reaction (PCR).&#xD;
&#xD;
      After the parent/adopter signs a parents/adopters information sheet (Informed Consent form)&#xD;
      for the child's participation in the clinical trial, the recording of medical history data, a&#xD;
      medical examination including the evaluation of symptoms on the Clinical Dehydration Scale&#xD;
      (CDS) by pediatrician, and laboratory tests will be performed during Visit 1 (Day 1). If&#xD;
      inclusion criteria are met and non-inclusion criteria are absent (day 1), the patient will be&#xD;
      included in the trial and randomized to administer either Ergoferon or Placebo.&#xD;
&#xD;
      In addition to the standard/pathogenetic therapies, group 1 patients will take Ergoferon&#xD;
      following a 5-day regimen, whereas group 2 patients will receive Placebo. The&#xD;
      parents/adopters of the patient will be provided with a patient diary and instructed how to&#xD;
      complete the diary.&#xD;
&#xD;
      Before treatment stool specimens will be collected from the patients for detection and&#xD;
      differentiation of Rotavirus A, Norovirus 2 genotype, Astrovirus, Adenovirus F, Shigella&#xD;
      spp., enteroinvasive E.coli (EIEC), Salmonella spp., and thermophilic Campylobacter spp.&#xD;
      using a PCR assay to diagnose the etiology of intestinal infection. In total, the patients&#xD;
      will be monitored for 10 days (screening, randomization, treatment initiation - Day 1; the&#xD;
      treatment on Days 1-5; observation in hospital - Day 6, and follow-up period - Day 7-10).&#xD;
      During the treatment and inpatient observation periods (Days 1-6, Visits 1-6), the patients&#xD;
      will be examined daily by a pediatrician, and the examination results, including the CDS&#xD;
      scores, will be recorded in source documents. The patient's parent/adopter will complete the&#xD;
      patient diary every day, recording the presence/absence of diarrhea signs, vomiting, and body&#xD;
      temperature. The pediatrician will check them each time for the correctness of completion. On&#xD;
      day 10 (after hospital discharge), Visit 7 will be done (as an in-person visit (a hospital or&#xD;
      calling a doctor) or a distance, 'phone' visit) to interview the parents/adopters about the&#xD;
      patient's health, presence of any complications, and use of medications (the pediatrician&#xD;
      will use this information to complete a questionnaire). Collection of stool specimens and&#xD;
      repeat PCR for Rotaviruses/Noroviruses/Astroviruses/Adenoviruses, Shigella spp., EIEC,&#xD;
      Salmonella spp., and Campylobacter spp. will be performed on Days 3, 4, and 6 of inpatient&#xD;
      observation and after discharge from the hospital (Day 10); collection of blood and urine&#xD;
      specimens for safety tests will be carried out at baseline and before hospital discharge (day&#xD;
      6). The recording of the intake of study therapies and of concomitant medications as well as&#xD;
      the assessment of compliance with and safety of the study therapies will be performed on Days&#xD;
      2-6 and 10.&#xD;
&#xD;
      Patients who recovered while in hospital and are discharged from the unit earlier than at 5&#xD;
      days will undergo the procedures of Visit 6, including the collection of biological specimens&#xD;
      for PCR (efficacy evaluation) and biochemistry, blood test and urinalysis (safety&#xD;
      assessment). The parents/adopters will be given the blister pack with the remaining study&#xD;
      drug so that the patient can continue the treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2016</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Diarrhea Duration.</measure>
    <time_frame>On days 1-10 of observation period.</time_frame>
    <description>Diarrhea duration is considered as the time between receiving the first dose of investigational medicine /placebo and the normal consistency of stool pattern (to the previous stool consistency before diarrhea), i.e.&#xD;
time to the first loose stool which is followed by two normal consistency stools over 24 h (infants may have three episodes of loose stool over a 24-hour period), or&#xD;
time to ≤3 episodes of stool occurring over 24 h, at least 2 of which are normal consistency stools, or&#xD;
time to the absence of stools for ≥12 h which is not followed by new episodes of diarrhea (total stool frequency over 24 h - less than 3 times).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Without Diarrhea.</measure>
    <time_frame>48, 72 and 96 hours of the treatment.</time_frame>
    <description>Based on medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Recovery.</measure>
    <time_frame>48, 72 and 96 hours of the treatment.</time_frame>
    <description>Based on medical records. Recovery criteria: absence of diarrhea, vomiting, symptoms of dehydration, and increased body temperature (based on daily examinations by pediatrician).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Illness Duration.</measure>
    <time_frame>On days 1-10 of observation period.</time_frame>
    <description>From the enrollment to the recovery. Recovery criteria: absence of diarrhea, vomiting, symptoms of dehydration, and increased body temperature (based on daily examinations by pediatrician).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clinical Dehydration Scale Score.</measure>
    <time_frame>24, 48, and 72 hours of the treatment.</time_frame>
    <description>Based on medical records. Clinical Dehydration Scale score is more or equal 1. Note: minimum values - 0 points, maximum values - 8 points. Interpretation: 0 points - no dehydration, from 1 to 4 points - light dehydration, 5-8 points - average/severe dehydration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Vomiting Duration (if Any).</measure>
    <time_frame>On days 1-10 of observation period.</time_frame>
    <description>Based on medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Negative PCR Tests.</measure>
    <time_frame>On days 3, 4, 6 and 10 of observation period.</time_frame>
    <description>Based on medical records.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Worsening of Illness and/or Hospital-acquired Infection.</measure>
    <time_frame>On days 1-10 of observation period.</time_frame>
    <description>Based on medical records. Worsening of illness: an increase in dehydration scores and worsening of non-specific symptoms, as evidenced by a decline in general appearance, increasing fatigue and drowsiness, refusal to eat and drink, severe tachycardia/bradycardia, unstable hemodynamics, tachypnea, hypo- or hyperventilation, circulation disorders, peripheral cyanosis, sunken eyes, severe dryness of skin and mucous/tongue, poor tissue turgor, absent tears, persistent vomiting, anuria/acute kidney injury, seizure/convulsions, and meningismus. Hospital-acquired infection: a viral or bacterial infection (intestinal, respiratory or urinary tract infection, etc.) occurring after at least 48 h of hospital stay and confirmed by laboratory tests.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">259</enrollment>
  <condition>Viral Intestinal Infection</condition>
  <arm_group>
    <arm_group_label>Ergoferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergoferon</intervention_name>
    <arm_group_label>Ergoferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients of both gender aged from 6 months to 6 years, who have been admitted to&#xD;
             infectious diseases unit.&#xD;
&#xD;
          2. Diarrhea (watery diarrhea at least 3 times a day).&#xD;
&#xD;
          3. CDS score of ≥1.&#xD;
&#xD;
          4. The first 48 hours from the onset of the first diarrhea episode.&#xD;
&#xD;
          5. Start of study treatment (Ergoferon/Placebo) within 12 hours after the start of the&#xD;
             standard hospital therapy.&#xD;
&#xD;
          6. Availability of a patient information sheet (Informed Consent form) signed by the&#xD;
             patient's parents/adopters to confirm the child's participation in the clinical trial&#xD;
             signed by one parent/adopter of the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suspected bacterial intestinal infection.&#xD;
&#xD;
          2. Suspected infectious diseases affecting other organ systems (e.g. pneumonia,&#xD;
             meningitis, sepsis, otitis media, urinary tract infection, etc.).&#xD;
&#xD;
          3. Severe intestinal infection.&#xD;
&#xD;
          4. Severe dehydration (CDS score ≥7).&#xD;
&#xD;
          5. Anuria (acute kidney injury).&#xD;
&#xD;
          6. Medical history or prior diagnosis of serious diseases, including primary/secondary&#xD;
             immunodeficiency, oncological disease, diabetes mellitus, infantile cerebral palsy,&#xD;
             mucoviscidosis/cystic fibrosis etc.&#xD;
&#xD;
          7. Exacerbation, or decompensation of chronic disease, including diseases of the&#xD;
             digestive system that would affect the patient's ability to participate in the&#xD;
             clinical trial.&#xD;
&#xD;
          8. Malabsorption syndrome, including congenital or acquired lactose intolerance/lactase&#xD;
             deficiency or any other disaccharidase deficiency and galactosemia.&#xD;
&#xD;
          9. Allergy/ intolerance to any of the components of medications used in the treatment.&#xD;
&#xD;
         10. Course intake of medicines listed in the section &quot;Prohibited concomitant treatment&quot;&#xD;
             for 2 weeks prior to the enrollment in the trial.&#xD;
&#xD;
         11. Participation in other clinical trials within 3 months prior to the enrollment in this&#xD;
             study.&#xD;
&#xD;
         12. Patients whose parents/adopters, from the investigator's point of view, will fail to&#xD;
             comply with the observation requirements of the trial or with the dosing regimen of&#xD;
             the study drugs.&#xD;
&#xD;
         13. Patient's parents/adopters are related to the research staff of the clinical&#xD;
             investigative site who are directly involved in the trial or are the immediate family&#xD;
             member of the researcher. The immediate family members include husband/wife, parents,&#xD;
             children or brothers (or sisters), regardless of whether they are natural or adopted.&#xD;
&#xD;
         14. The patient's parent/adopter works for MATERIA MEDICA HOLDING (i.e., is the company's&#xD;
             employee, temporary contract worker or appointed official responsible for carrying out&#xD;
             the research) or the immediate relative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>State budgetary Health Care institution of the Arkhangelsk region &quot;Arkhangelsk Regional Pediatric Clinical Hospital named after PG Vyzhletsova&quot;</name>
      <address>
        <city>Arkhangel'sk</city>
        <zip>163002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution of Higher Professional Education &quot;Urals State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Kazan Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Kazan'</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal Budget Institution of Science &quot;Central Research Institute of Epidemiology&quot; of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pirogov Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Orenburg State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Budgetary Health Care Institution &quot;Semashko City Hospital №1 Rostov-on-Don &quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Saint Petersburg State Pediatric Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sailnt Petersburg State Budgetary Health Care Institution &quot;City Child Hospital №22&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196657</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution &quot;Scientific Research Institute of Children's Infections Federal Biomedical Agency&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Budget Educational institution of High Professional Training Smolensk State Medical University of Ministry of Health Care of the Russian Federation</name>
      <address>
        <city>Smolensk</city>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Yaroslavl State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Institute of Virology of Ministry of Health of Republic Uzbekistan</name>
      <address>
        <city>Tashkent</city>
        <zip>100194</zip>
        <country>Uzbekistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Uzbekistan</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <results_first_submitted>August 27, 2020</results_first_submitted>
  <results_first_submitted_qc>September 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2020</results_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03039699/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ergoferon</title>
          <description>Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.&#xD;
Ergoferon</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Incorrect inclusion</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of data to assess study endpoint</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bacterial infection</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ergoferon</title>
          <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 tablet 3 times a day&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="259"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="127"/>
                    <count group_id="B2" value="132"/>
                    <count group_id="B3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="127"/>
                    <count group_id="B2" value="132"/>
                    <count group_id="B3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="1.5"/>
                    <measurement group_id="B2" value="2.3" spread="1.4"/>
                    <measurement group_id="B3" value="2.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="127"/>
                    <count group_id="B2" value="132"/>
                    <count group_id="B3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Uzbekistan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="127"/>
                    <count group_id="B2" value="132"/>
                    <count group_id="B3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="127"/>
                    <count group_id="B2" value="132"/>
                    <count group_id="B3" value="259"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Diarrhea Duration.</title>
        <description>Diarrhea duration is considered as the time between receiving the first dose of investigational medicine /placebo and the normal consistency of stool pattern (to the previous stool consistency before diarrhea), i.e.&#xD;
time to the first loose stool which is followed by two normal consistency stools over 24 h (infants may have three episodes of loose stool over a 24-hour period), or&#xD;
time to ≤3 episodes of stool occurring over 24 h, at least 2 of which are normal consistency stools, or&#xD;
time to the absence of stools for ≥12 h which is not followed by new episodes of diarrhea (total stool frequency over 24 h - less than 3 times).</description>
        <time_frame>On days 1-10 of observation period.</time_frame>
        <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Average Diarrhea Duration.</title>
          <description>Diarrhea duration is considered as the time between receiving the first dose of investigational medicine /placebo and the normal consistency of stool pattern (to the previous stool consistency before diarrhea), i.e.&#xD;
time to the first loose stool which is followed by two normal consistency stools over 24 h (infants may have three episodes of loose stool over a 24-hour period), or&#xD;
time to ≤3 episodes of stool occurring over 24 h, at least 2 of which are normal consistency stools, or&#xD;
time to the absence of stools for ≥12 h which is not followed by new episodes of diarrhea (total stool frequency over 24 h - less than 3 times).</description>
          <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" lower_limit="37.9" upper_limit="49"/>
                    <measurement group_id="O2" value="54.7" lower_limit="49" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Without Diarrhea.</title>
        <description>Based on medical records.</description>
        <time_frame>48, 72 and 96 hours of the treatment.</time_frame>
        <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Without Diarrhea.</title>
          <description>Based on medical records.</description>
          <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours timepoint comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0675</p_value>
            <p_value_desc>p-value adjusted for multiple comparisons using Holm method</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours timepoint comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0675</p_value>
            <p_value_desc>p-value adjusted for multiple comparisons using Holm method</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours timepoint comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5569</p_value>
            <p_value_desc>p-value adjusted for multiple comparisons using Holm method</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Recovery.</title>
        <description>Based on medical records. Recovery criteria: absence of diarrhea, vomiting, symptoms of dehydration, and increased body temperature (based on daily examinations by pediatrician).</description>
        <time_frame>48, 72 and 96 hours of the treatment.</time_frame>
        <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Recovery.</title>
          <description>Based on medical records. Recovery criteria: absence of diarrhea, vomiting, symptoms of dehydration, and increased body temperature (based on daily examinations by pediatrician).</description>
          <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours timepoint comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0696</p_value>
            <p_value_desc>p-value adjusted for multiple comparisons using Holm method</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours timepoint comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0696</p_value>
            <p_value_desc>p-value adjusted for multiple comparisons using Holm method</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours timepoint comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1998</p_value>
            <p_value_desc>p-value adjusted for multiple comparisons using Holm method</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Illness Duration.</title>
        <description>From the enrollment to the recovery. Recovery criteria: absence of diarrhea, vomiting, symptoms of dehydration, and increased body temperature (based on daily examinations by pediatrician).</description>
        <time_frame>On days 1-10 of observation period.</time_frame>
        <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Average Illness Duration.</title>
          <description>From the enrollment to the recovery. Recovery criteria: absence of diarrhea, vomiting, symptoms of dehydration, and increased body temperature (based on daily examinations by pediatrician).</description>
          <population>2 patients in Ergoferon group and 2 patients in Placebo group had no primary outcome data</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" lower_limit="35.3" upper_limit="46.3"/>
                    <measurement group_id="O2" value="53.0" lower_limit="47.2" upper_limit="58.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0039</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Clinical Dehydration Scale Score.</title>
        <description>Based on medical records. Clinical Dehydration Scale score is more or equal 1. Note: minimum values - 0 points, maximum values - 8 points. Interpretation: 0 points - no dehydration, from 1 to 4 points - light dehydration, 5-8 points - average/severe dehydration.</description>
        <time_frame>24, 48, and 72 hours of the treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Clinical Dehydration Scale Score.</title>
          <description>Based on medical records. Clinical Dehydration Scale score is more or equal 1. Note: minimum values - 0 points, maximum values - 8 points. Interpretation: 0 points - no dehydration, from 1 to 4 points - light dehydration, 5-8 points - average/severe dehydration.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.3" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.2" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.2" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>The p-value associated with &quot;treatment*visit&quot; interaction of total CDS score from 24 hours to 48 and 72 hours of treatment between Ergoferon and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Vomiting Duration (if Any).</title>
        <description>Based on medical records.</description>
        <time_frame>On days 1-10 of observation period.</time_frame>
        <population>Vomiting occured in 64.8% patients of Ergoferon group and 71.1% patients of placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Average Vomiting Duration (if Any).</title>
          <description>Based on medical records.</description>
          <population>Vomiting occured in 64.8% patients of Ergoferon group and 71.1% patients of placebo group.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" lower_limit="35.1" upper_limit="54.1"/>
                    <measurement group_id="O2" value="57.9" lower_limit="48.4" upper_limit="67.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0044</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Negative PCR Tests.</title>
        <description>Based on medical records.</description>
        <time_frame>On days 3, 4, 6 and 10 of observation period.</time_frame>
        <population>PCR tests on days 4, 6 and 10 were run on less patients due to technical issues in laboratory</population>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Negative PCR Tests.</title>
          <description>Based on medical records.</description>
          <population>PCR tests on days 4, 6 and 10 were run on less patients due to technical issues in laboratory</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="69"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5488</p_value>
            <p_value_desc>nonadjusted p-value</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4 comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8140</p_value>
            <p_value_desc>nonadjusted p-value</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6 comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1248</p_value>
            <p_value_desc>nonadjusted p-value</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 10 comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3889</p_value>
            <p_value_desc>nonadjusted p-value</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Worsening of Illness and/or Hospital-acquired Infection.</title>
        <description>Based on medical records. Worsening of illness: an increase in dehydration scores and worsening of non-specific symptoms, as evidenced by a decline in general appearance, increasing fatigue and drowsiness, refusal to eat and drink, severe tachycardia/bradycardia, unstable hemodynamics, tachypnea, hypo- or hyperventilation, circulation disorders, peripheral cyanosis, sunken eyes, severe dryness of skin and mucous/tongue, poor tissue turgor, absent tears, persistent vomiting, anuria/acute kidney injury, seizure/convulsions, and meningismus. Hospital-acquired infection: a viral or bacterial infection (intestinal, respiratory or urinary tract infection, etc.) occurring after at least 48 h of hospital stay and confirmed by laboratory tests.</description>
        <time_frame>On days 1-10 of observation period.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergoferon</title>
            <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 tablet 3 times a day&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Worsening of Illness and/or Hospital-acquired Infection.</title>
          <description>Based on medical records. Worsening of illness: an increase in dehydration scores and worsening of non-specific symptoms, as evidenced by a decline in general appearance, increasing fatigue and drowsiness, refusal to eat and drink, severe tachycardia/bradycardia, unstable hemodynamics, tachypnea, hypo- or hyperventilation, circulation disorders, peripheral cyanosis, sunken eyes, severe dryness of skin and mucous/tongue, poor tissue turgor, absent tears, persistent vomiting, anuria/acute kidney injury, seizure/convulsions, and meningismus. Hospital-acquired infection: a viral or bacterial infection (intestinal, respiratory or urinary tract infection, etc.) occurring after at least 48 h of hospital stay and confirmed by laboratory tests.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3593</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse/Serious adverse events were collected for 10 days of the therapy and follow-up periods.</time_frame>
      <desc>Adverse/Serious adverse events were collected in patients of the Safety population (n=259).</desc>
      <group_list>
        <group group_id="E1">
          <title>Ergoferon</title>
          <description>1 tablet 3 times a day&#xD;
Ergoferon</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 tablet 3 times a day&#xD;
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Purine metabolism disorder</sub_title>
                <description>Functional stomach upset. Disoder of purine metabolism (acetone vomiting).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Increased levels of ALT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Increased levels of AST</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Increase in the percentage of lymphocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Decrease in the percentage of neutrophils</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hematochezia</sub_title>
                <description>The presence of blood in the stool.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Acute otitis media</sub_title>
                <description>Left-sided otitis media (acute, non-suppurative)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Candida Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Positive test result for staphylococcus</sub_title>
                <description>Positive result of isolation and identification of staphylococcus. Discharge of staphylococcus from the nasopharynx.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Herpangina caused by Coxsackie virus</sub_title>
                <description>Vesicular pharyngitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes in urine</sub_title>
                <description>An increase in the number of leukocytes in the urine.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="132"/>
              </event>
              <event>
                <sub_title>Hyperphosphaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="132"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikhail Putilovskiy, MD, PhD, Clinical and Medical Department Director</name_or_title>
      <organization>Materia Medica Holding</organization>
      <phone>+74952761571 ext 302</phone>
      <email>PutilovskiyMA@materiamedica.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

